A subanalysis of the SAMMPRIS (Stenting vs. aggressive medical therapy for intracranial arterial stenosis) trial found that there were lower outcome events with aggressive medical management than with stenting, even in patients who had failed antithrombotic therapy, who are perceived as being at high-risk.
Greater calcium build-up in arteries outside the brain may be associated with brain changes linked to future risk of dementia and stroke, according to new research published in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.
On 8 February, The board of directors of Stryker announced that Stephen P MacMillan has resigned as chairman, president and CEO for family reasons, effective immediately. Curt Hartman, vice president and chief financial officer, has been named interim chief executive officer and William U Parfet, lead independent director, becomes non-executive chairman. The board has begun a search for a permanent successor to MacMillan and will consider both internal and external candidates.
An experimental drug, clazosentan, reduced the risk of blood vessel spasm in patients with a brain aneurysm, according to research presented at the American Stroke Association’s International Stroke Conference 2012.
On 1 December, Covidien announced that the US Food and Drug Administration (FDA) has cleared SpiderFX for the treatment of severely calcified lesions used in conjunction with plaque excision in arteries of the lower extremities. It is the only embolic protection device indicated for this treatment in the United States.
On 15 ovember, DFine announced the initiation of a prospective randomised clinical study to evaluate the clinical effectiveness of minimally invasive augmentation procedures to treat vertebral compression fractures.
Flow diversion is a new approach for the endovascular treatment of intracranial aneurysms. The Woven Endobridge (WEB II, from Sequent Medical) cerebral aneurysm embolization device is an intrasaccular, oblate, braided-wire designed to provide flow disruption at the aneurysm neckparent artery interface. A new study suggests that early data from the first two patients treated with the device is hopeful.
The US Food and Drug Administration has allowed marketing of the first hand-held device intended to aid in the detection of intracranial hematomas, using near-infrared spectroscopy. The device, called the Infrascanner Model 1000 from InfraScan can help health care providers identify patients with critical head injuries who need an immediate brain imaging study.
The Shield Kyphoplasty system is designed to give the physician control of cement placement during vertebral augmentation procedures.
Based on a review of the safety data from a first dose cohort of three patients treated with ReN001—a stem cell therapy for disabled stroke patients—, ReNeuron announced on 1 September that the independent Data Safety Monitoring Board (DSMB) for its clinical trial had recommended advancement of the study to the evaluation of a higher dose of ReN001. ReNeuron reported that the first patient in this next dose cohort of three patients has been successfully treated and discharged from hospital with no acute safety issues arising.
GE Healthcare introduced the Innova IGS 630 biplane cardiovascular and interventional imaging system at the Radiological Society of orth America 2011 meeting in Chicago. The system features Innova CT HDii 3D technology and a comprehensive set of advanced applications for interventional neuroradiology.
InVivo Therapeutics and Geisinger Health System announced a research collaboration to conduct a preclinical study using InVivo’s injectable biocompatible hydrogel for the treatment of chronic pain caused by peripheral nerve compression. InVivo expects to submit data from the study to the US Food and Drug Administration (FDA) in 2012 representing the company’s first technology to treat degenerative neurologic conditions outside of the spinal cord.
The largest randomised, controlled study on the clinical effectiveness of coils establishes the procedure as a safe and effective treatment for ruptured and unruptured aneurysms. In the trial, 96% of patients with unruptured aneurysms and 90% of patients with acutely ruptured aneurysms were alive and free of disability out to 15 months after treatment. The results of the MAPS (Matrix and platinum science) trial were announced during the Society of (euroInterventional Surgery (S(IS) 8th Annual Meeting in Colorado Springs, USA.
On 29 December 2011, MindFrame announced that a CE mark was granted for a new series of MindFrame Capture LP devices. The low profile devices have been expanded to include a 4-mm diameter and shorter length sizes. The Capture LP devices can be deployed through smaller microcatheters to improve navigation through tortuous vessels.
The market for the specialised devices used for neurosurgical and neurovascular treatments will grow to US$240 million by 2016, according to research made by Millenium Research Group (MRG).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos